Get the Stockscreener App
6.78
2.02%
-0.14
Kyntra Bio Inc stock is traded at $6.78, with a volume of 7,811.
It is down -2.02% in the last 24 hours and down -9.60% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$6.92
Open:
$6.93
24h Volume:
7,811
Relative Volume:
0.42
Market Cap:
$27.91M
Revenue:
$8.30M
Net Income/Loss:
$-52.26M
P/E Ratio:
0.1724
EPS:
39.3379
Net Cash Flow:
$-17.14M
1W Performance:
-2.73%
1M Performance:
-9.60%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.75
$7.2008
1-Week Range:
$6.72
$7.2008
52-Week Range:
$6.72
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
6.90 | 27.99M | 8.30M | -52.26M | -17.14M | 39.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Kyntra Bio Charts a New Course in Oncology - AD HOC NEWS
KYNB SEC FilingsKYNTRA BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
KYNB Stock Price, Forecast & Analysis | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio (KYNB) Stock Price, News & Analysis - MarketBeat
What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB) - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
KYNB: Kyntra Bio IncFull Company Report - Zacks Investment Research
FibroGen rebrands as Kyntra Bio, refocuses on oncology - TipRanks
FibroGen announces rebrand as Kyntra Bio - TipRanks
FibroGen stock rises after announcing rebrand to Kyntra Bio - Investing.com
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB - Investing.com
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewswire
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
FibroGen Sells China Unit To AstraZeneca And Refocuses - Finimize
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
FibroGen Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
FGENFibrogen Inc Latest Stock News & Market Updates - Stock Titan
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - marketscreener.com
FibroGen: Q1 Earnings Snapshot - marketscreener.com
FGEN Stock Price, News & Analysis - Stock Titan
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - marketscreener.com
FibroGen: Q4 Earnings Snapshot - marketscreener.com
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
FibroGen, Inc. Announces Cessation of Christine L. Chung as Senior Vice President, China Operations - marketscreener.com
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer - marketscreener.com
FibroGen: Q3 Earnings Snapshot - marketscreener.com
FibroGen to Report Third Quarter 2024 Financial Results - marketscreener.com
Kyntra Bio Inc (KYNB) Stock Price Quote Today & Current Price Chart - Capital.com
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference - marketscreener.com
FibroGen: Q2 Earnings Snapshot - marketscreener.com
FibroGen to Report Second Quarter 2024 Financial Results - marketscreener.com
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference - marketscreener.com
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference - marketscreener.com
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kyntra Bio Inc Stock (KYNB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):